Literature DB >> 19296096

Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data.

Cyril Rauch1.   

Abstract

Based on molecular and physiological resemblance, the mechanism that controls drug bioavailability and toxicity also shares strong similarities to the one that controls drug resistance. In both cases, this mechanism relies on the expression of drug transporters and the physico-chemical properties of drugs, which together alter the intracellular accumulation of chemicals in cells or tissues. However, a parameter that is central and has received great attention in the field of bioavailability, but almost none in the field of drug resistance, is the molecular weight of drugs. In the former area, it is well known that to achieve a reasonable bioavailability, drugs must have-among other properties-a molecular weight less than 500, known as Lipinski's 2nd rule. Accordingly, it is worth questioning whether a similar rule exists in the field of drug resistance and what subsequent mechanism would control the membrane permeability to drugs as a function of their molecular weight. I demonstrate here that cytosolic pH fixes the molecular weight of drugs entering cells, by altering the cell membrane mechanical properties and that, both cytosolic pH and membrane mechanical properties are needed and sufficient to explain doxorubicin resistance levels in different cancerous cell lines. Finally, I discuss the efficiency of a drug handling activity by transporters in MDR and suggest ways to control drug delivery mechanically. In addition, and for the first time, the literal expression of a Law similar to Lipinski's 2nd rule will be described as a function of cytosolic pH and lipid number asymmetry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296096     DOI: 10.1007/s00249-009-0429-x

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  59 in total

1.  Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry.

Authors:  C Rauch; E Farge
Journal:  Biophys J       Date:  2000-06       Impact factor: 4.033

Review 2.  Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane.

Authors:  J Ferté
Journal:  Eur J Biochem       Date:  2000-01

3.  Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein.

Authors:  A B Shapiro; V Ling
Journal:  Eur J Biochem       Date:  1997-11-15

4.  Tamoxifen inhibits acidification in cells independent of the estrogen receptor.

Authors:  N Altan; Y Chen; M Schindler; S M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 5.  The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature.

Authors:  Salvador Harguindey; Gorka Orive; José Luis Pedraz; Angelo Paradiso; Stephan J Reshkin
Journal:  Biochim Biophys Acta       Date:  2005-09-25

6.  Packing constraints and electrostatic surface potentials determine transmembrane asymmetry of phosphatidylethanol.

Authors:  A V Victorov; N Janes; T F Taraschi; J B Hoek
Journal:  Biophys J       Date:  1997-06       Impact factor: 4.033

7.  Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein.

Authors:  P D Roepe; L Y Wei; J Cruz; D Carlson
Journal:  Biochemistry       Date:  1993-10-19       Impact factor: 3.162

8.  Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.

Authors:  A Seidel; M Hasmann; R Löser; A Bunge; B Schaefer; I Herzig; K Steidtmann; M Dietel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Alterations of vinblastine influx in multidrug-resistant lymphoblastic leukaemic CEM cells.

Authors:  M Colin; C Madoulet; L Warren; J C Jardillier
Journal:  Anticancer Res       Date:  1996 Jan-Feb       Impact factor: 2.480

10.  Multi drug resistance-dependent "vacuum cleaner" functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density.

Authors:  Cyril Rauch; Alain Pluen
Journal:  Eur Biophys J       Date:  2007-01-09       Impact factor: 2.095

View more
  11 in total

Review 1.  On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the "space-time" dimension of MDR.

Authors:  Vasiliki Panagiotopoulou; Giles Richardson; Oliver E Jensen; Cyril Rauch
Journal:  Eur Biophys J       Date:  2009-11-04       Impact factor: 1.733

2.  Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids.

Authors:  Vijay Raghavan; Sivakumar Vijayaraghavalu; Chiranjeevi Peetla; Masayoshi Yamada; Megan Morisada; Vinod Labhasetwar
Journal:  Langmuir       Date:  2015-10-15       Impact factor: 3.882

Review 3.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

Review 4.  Cell membrane modulation as adjuvant in cancer therapy.

Authors:  Sara Zalba; Timo L M Ten Hagen
Journal:  Cancer Treat Rev       Date:  2016-11-09       Impact factor: 12.111

5.  Proton dynamics in cancer.

Authors:  Veronica Huber; Angelo De Milito; Salvador Harguindey; Stephan J Reshkin; Miriam L Wahl; Cyril Rauch; Antonio Chiesi; Jacques Pouysségur; Robert A Gatenby; Licia Rivoltini; Stefano Fais
Journal:  J Transl Med       Date:  2010-06-15       Impact factor: 5.531

6.  Importance of the difference in surface pressures of the cell membrane in doxorubicin resistant cells that do not express Pgp and ABCG2.

Authors:  Charlotte Bell; Claire Hill; Christopher Burton; Adam Blanchard; Freya Shephard; Cyril Rauch
Journal:  Cell Biochem Biophys       Date:  2013-07       Impact factor: 2.194

Review 7.  Acid-mediated Lipinski's second rule: application to drug design and targeting in cancer.

Authors:  Ziad Omran; Cyril Rauch
Journal:  Eur Biophys J       Date:  2014-04-01       Impact factor: 1.733

8.  Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.

Authors:  Luana Lugini; Ilaria Sciamanna; Cristina Federici; Elisabetta Iessi; Enrico Pierluigi Spugnini; Stefano Fais
Journal:  Oncotarget       Date:  2017-01-17

9.  Proton pump inhibitors for the treatment of cancer in companion animals.

Authors:  Megan Walsh; Stefano Fais; Enrico Pierluigi Spugnini; Salvador Harguindey; Tareq Abu Izneid; Licia Scacco; Paula Williams; Cinzia Allegrucci; Cyril Rauch; Ziad Omran
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04

Review 10.  Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.

Authors:  Salvador Harguindey; Jose Luis Arranz; Julian David Polo Orozco; Cyril Rauch; Stefano Fais; Rosa Angela Cardone; Stephan J Reshkin
Journal:  J Transl Med       Date:  2013-11-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.